RxDoctor Payments DataLook up a doctor →

Douglas Langford, MD

Neurology · Provo, UTNPI 1659343564

Payments from drug & device makers

$91,915in general payments, 2019–2025

Across 2,946 payments — averaging $31.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$32K
  • Pfizer$22K
  • AbbVie$5K
  • Biohaven Pharmaceutical Holding Company Ltd.$3K
  • EMD Serono, Inc.$3K
  • Novartis$2K
  • plus $24K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biohaven Pharmaceuticals, Inc.66$32,386
Pfizer89$21,918
AbbVie(2 entities)513$5,368
Biohaven Pharmaceutical Holding Company Ltd.44$3,375
EMD Serono, Inc.223$2,601
Novartis188$2,149
UCB, Inc.142$2,038
Teva Pharmaceuticals USA, Inc.214$1,769
Biogen93$1,596
AstraZeneca52$1,078
Medtronic(2 entities)46$1,038
SK Life Science, Inc.59$1,034
Neurocrine Biosciences, Inc.80$1,019
Bristol Myers Squibb88$933
TG Therapeutics, Inc.54$880
Acadia Pharmaceuticals Inc75$854
Amgen(2 entities)55$785
Sanofi44$726
MDD US Operations, LLC50$697
Argenx US, Inc.45$677
Genentech USA, Inc.50$659
Lilly USA, LLC43$605
Amneal Pharmaceuticals LLC38$580
Zyla Life Sciences, Inc.148$556
Lundbeck LLC35$489
Livanova USA, Inc.26$477
Johnson & Johnson(2 entities)24$399
Supernus Pharmaceuticals, Inc.39$357
Sunovion Pharmaceuticals Inc.26$344
Jazz Pharmaceuticals Inc.18$335
Upsher-smith Laboratories LLC19$313
Adamas Pharmaceuticals, Inc.26$300
Impel Pharmaceuticals Inc.27$261
Kyowa Kirin, Inc.14$256
Avanir Pharmaceuticals, Inc.15$243
Greenwich Biosciences, Inc.15$236
Axsome Therapeutics, Inc.22$232
Banner Life Sciences, LLC14$229
Boston Scientific13$213
Tanabe Pharma America, Inc.13$198
Takeda Pharmaceuticals U.S.A., Inc.9$189
Grifols USA, LLC10$188
Neurelis, Inc.10$150
Acorda Therapeutics, Inc8$129
CSL Behring6$127
Eisai Inc.6$118
Sumitomo Pharma America, Inc.8$115
ANI Pharmaceuticals, Inc.4$82
Catalyst Pharmaceuticals, Inc.4$67
Otsuka America Pharmaceutical, Inc.3$60
Cycle Pharmaceuticals Inc4$59
Akcea Therapeutics, Inc.3$51
Abbott3$50
Alnylam Pharmaceuticals Inc.3$41
Neuropace, Inc.2$37
Avion Pharmaceuticals2$33
Almatica Pharma LLC2$31
Assertio Therapeutics, Inc.4$29
Averitas Pharma Inc.1$21
Ipsen Biopharmaceuticals, Inc1$21

How this compares

$91,915 in reported general payments places this provider in the 85th percentile of 157 neurology providers in Utah.

See all neurology providers in Utah →

Medicare billing

Part B allowed, 2024
$156,528
Medicare patients
369
Services billed
8,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Provo

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →